[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641471":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":44,"centralContacts":44,"locations":45,"responsibleParty":81,"collaborators":85,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":44,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":44,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":44,"overallStatus":107,"whyStopped":44,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Liaquat University of Medical & Health Sciences","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Dispepril®","EXPERIMENTAL","Participants will receive Dispepril®, administered as two gastro-protected tablets daily for 14 consecutive days. One tablet will be taken approximately 15 minutes before lunch and one tablet approximately 15 minutes before dinner. Each tablet contains 300 mg of highly standardized Zingiber officinale extract and 150 mg of a patented bi-fractionated Perilla frutescens extract.",[13],"Dietary Supplement: Dispepril® (Pharmextracta S.p.A. Pontenure, Italy)",{"label":15,"type":10,"description":16,"interventionNames":17},"Half-Dose PPI Plus Dispepril®","Participants will receive a half-dose proton pump inhibitor once daily together with Dispepril® administered as two gastro-protected tablets daily for 14 consecutive days. One tablet will be taken approximately 15 minutes before lunch and one tablet approximately 15 minutes before dinner.",[18],"Combination Product: Half-Dose PPI Plus Dispepril®",{"label":20,"type":21,"description":22,"interventionNames":23},"Full-Dose PPI","ACTIVE_COMPARATOR","Participants will receive a full-dose proton pump inhibitor once daily for 14 consecutive days according to standard clinical practice for functional dyspepsia.",[24],"Drug: Full-Dose Proton Pump Inhibitor",[26,33,39],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DIETARY_SUPPLEMENT","Dispepril® (Pharmextracta S.p.A. Pontenure, Italy)","Dispepril® is a gastro-protected dietary supplement containing 300 mg of highly standardized Zingiber officinale extract titrated to 10% gingerols and shogaols and 150 mg of a patented bi-fractionated Perilla frutescens extract per tablet.",[9],[32],"Ginger Extract, Perilla Extract",{"type":34,"name":15,"description":35,"armGroupLabels":36,"otherNames":37},"COMBINATION_PRODUCT","Participants will receive a half-dose proton pump inhibitor once daily together with Dispepril® administered as two gastro-protected tablets daily for 14 consecutive days.",[15],[38],"PPI + Dispepril®",{"type":40,"name":41,"description":22,"armGroupLabels":42,"otherNames":43},"DRUG","Full-Dose Proton Pump Inhibitor",[20],[20],null,[46,57,65,73],{"facility":47,"status":44,"city":48,"state":44,"zip":44,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":44},"U.O.S.D. Digestive Endoscopy, Interventional and Emergency Unit","Montevarchi","Italy","IT",{"type":52,"coordinates":53},"Point",[54,55],11.57238,43.5252,{"lat":55,"lon":54},{"facility":58,"status":44,"city":59,"state":44,"zip":44,"country":49,"countryCode":50,"cosmosGeoPoint":60,"geoPoint":64,"contacts":44},"University of Rome Tor Vergata","Rome",{"type":52,"coordinates":61},[62,63],12.51133,41.89193,{"lat":63,"lon":62},{"facility":66,"status":44,"city":67,"state":44,"zip":44,"country":49,"countryCode":50,"cosmosGeoPoint":68,"geoPoint":72,"contacts":44},"Gastroenterology Centre","Salerno",{"type":52,"coordinates":69},[70,71],14.79328,40.67545,{"lat":71,"lon":70},{"facility":74,"status":44,"city":75,"state":44,"zip":44,"country":49,"countryCode":50,"cosmosGeoPoint":76,"geoPoint":80,"contacts":44},"University of Urbino Carlo Bo","Urbino",{"type":52,"coordinates":77},[78,79],12.63633,43.72621,{"lat":79,"lon":78},{"type":82,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"PRINCIPAL_INVESTIGATOR","Dr. Amjad Khan","Professor of Clinical Biochemistry and Experimental Medicine",[86],{"name":87,"class":6},"University of Urbino \"Carlo Bo\"","100641471","assessment-of-the-efficacy-of-a-highly-standardized-ginger-and-perilla-nutraceutical-dispepril-in-improving-gastric-and-intestinal-symptoms-in-patients-with-functional-dyspepsia-100641471",false,"NCT07655219","Assessment of the Efficacy of a Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia","Assessment of the Efficacy of a Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia: A Multicenter, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Male or female participants aged 18 to 65 years\n* Diagnosis of functional dyspepsia according to Rome IV criteria\n* Willingness and ability to provide written informed consent\n* Ability to follow study product administration instructions\n* Ability to attend scheduled study visits\n\nExclusion Criteria:\n\n* Gastrectomy\n* Cancer\n* Use of NSAIDs, cholagogues, or tricyclic antidepressants within 30 days prior to enrollment\n* Helicobacter pylori positivity\n* Alcoholism or other substance abuse\n* Hepatic disease\n* Renal disease\n* History of hypersensitivity to formulation active ingredients or excipients\n* Pregnancy or breastfeeding\n* Participation in another clinical trial or completion of another clinical trial within 1 month prior to enrollment\n* Refusal or inability to provide informed consent","ALL","18 Years","65 Years",{"count":99,"type":100},400,"ESTIMATED","INTERVENTIONAL",[103],"NA","This multicenter, prospective, randomized, controlled clinical trial aims to evaluate the efficacy of a nutraceutical treatment containing highly standardized extracts of ginger (Zingiber officinale) and perilla (Perilla frutescens) (Dispepril®, Pharmextracta S.p.A. Pontenure, Italy) in improving gastric and intestinal symptoms in adults with functional dyspepsia. The study will assess the non-inferiority of Dispepril® compared with standard proton pump inhibitor (PPI) therapy in reducing postprandial distress symptoms. Participants will be randomized in a 2:1:1 ratio to receive Dispepril® alone, Dispepril® plus half-dose PPI, or full-dose PPI for 14 days. Efficacy will be assessed using the Leuven Postprandial Distress Scale (LPDS), together with evaluations of treatment tolerability, adherence, and adverse events.",[106],"Functional Dysphonia","NOT_YET_RECRUITING","2026-06-15",{"date":110,"type":111},"2026-06-17","ACTUAL",{"date":113,"type":100},"2026-06-22",{"date":115,"type":100},"2026-11-30",{"name":5,"class":6},4]